What I hear is that the pharma industry (and Wall Street) is holding its breath for Amylin's next big thing: Exenatide (produced in partnership with Eli Lilly & Co.). This is another injectable product (derived from lizard saliva, of all things!) that, if approved by the FDA in a few months, will be offered in a pen delivery system. This one's mainly for Type 2 diabetics, and clinical studies have shown "marked reductions in blood sugar as measured by A1C, a measure that reflects a person's average blood sugar levels over the prior three- to four-month period."










Um, any patients out there really excited yet?

Yes, analysts expect the market for Symlin to be $300 million annually, at most, while Exenatide has the potential to become a $1 billion a year drug (!!)

Great, if it can help people. But what bothers me is that the news is all about the commercial potential, and which drug might "outperform" others in terms of sales numbers. Amylin's stock has jumped, and all the buzz is about when and how much it might climb further once Exenatide hits the streets?!

Disclaimer: Content created by the Diabetes Mine team. For more details click here.


This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.